2024
Living Flat: Stories from Women of Color After Mastectomy
Khubchandani J, Suttiratana S, Washington R, White-Bracey D, KC M, Silber A, Fayanju O, Butler P, Menon A, Greenup R. Living Flat: Stories from Women of Color After Mastectomy. Annals Of Surgical Oncology 2024, 1-11. PMID: 39407064, DOI: 10.1245/s10434-024-16337-y.Peer-Reviewed Original ResearchCancer stigmaKnowledge of family historyBreast cancer stigmaPatient-reported outcome measuresBreast cancerCommunity-partnered studyTeam-based approachPatient-reported outcomesWomen of color livingPost-mastectomy breast reconstructionQuality of lifeHealth QuestionnaireEthnic disparitiesInterview guideSemistructured interviewsThemes related to cultureResultsThe final cohortOutcome measuresWhite womenConclusionAmong womenFamily historyBreast reconstructionAdvocacy effortsStigmaFinal cohortASO Visual Abstract: National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. ASO Visual Abstract: National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 31: 9113-9113. DOI: 10.1245/s10434-024-16259-9.Peer-Reviewed Original ResearchNational Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 31: 9088-9099. PMID: 39322830, DOI: 10.1245/s10434-024-16107-w.Peer-Reviewed Original ResearchHR patientsLymph nodesRate of neoadjuvant chemotherapyHospital admissionNational patterns of careEmergency departmentDecrease wound complicationsNeoadjuvant chemo-Hospital re-admissionNeoadjuvant chemotherapyIn-hospital admissionRate of reconstructionPerioperative outcomesPostoperative hematomaComplication ratePostoperative complicationsWound complicationsHome recoveryPatterns of careBreast cancerMastectomyEmergency room visitsMultivariate analysisComplicationsPatientsIncidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers
Dey P, Kc M, Proussaloglou E, Khubchandani J, Kim L, Zanieski G, Park T, Lynch M, Gillego A, Valero M, Schneider E, Golshan M, Greenup R, Berger E. Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. Annals Of Surgical Oncology 2024, 31: 8821-8828. PMID: 39240394, DOI: 10.1245/s10434-024-16124-9.Peer-Reviewed Original ResearchTriple-negative breast cancerClinically node-negativePathologically node-negativePN+ diseaseNode-negativeBreast cancerYears of ageNodal diseaseHR-/HER2Significant comorbiditiesEpidermal growth factor receptor 2-positiveOdds of node positivityRate of nodal diseaseTriple-positive breast cancerTriple positive breast cancerEarly-stage breast cancerHR-positive/HER2-negativePathologic nodal diseasePathologic nodal positivityPredictors of pN+T1a breast cancerHR-/HER2+Sentinel node biopsyNational Cancer DatabasePathologic nodal stageComparison of incident breast cancer cases in the largest national US tumor registries
Plichta J, Thomas S, Chanenchuk T, Chan K, Hyslop T, Hwang E, Greenup R. Comparison of incident breast cancer cases in the largest national US tumor registries. Cancer 2024 PMID: 39154223, DOI: 10.1002/cncr.35525.Peer-Reviewed Original ResearchIncident breast cancer casesUS Cancer StatisticsBreast cancer casesNational Cancer DatabaseNon-HispanicNon-Hispanic American Indian/Alaska NativesCancer casesTumor RegistryIn situ breast cancerPopulation cancer registryNon-Hispanic blacksSamples of breast cancer patientsNon-Hispanic whitesAmerican Indian/Alaska NativeEnd Results ProgramBreast cancerPacific IslandersCancer RegistryCancer statisticsIndian/Alaska NativeCase ascertainmentInterpretation of findingsResults ProgramBreast cancer patientsRegistryASO Author Reflections: “Peace of Mind” After Surgery for Breast Cancer: Implications for Preference-Sensitive Shared Decision Making
Hamid S, Schultz K, Greenup R. ASO Author Reflections: “Peace of Mind” After Surgery for Breast Cancer: Implications for Preference-Sensitive Shared Decision Making. Annals Of Surgical Oncology 2024, 31: 5209-5210. PMID: 38713391, DOI: 10.1245/s10434-024-15408-4.Peer-Reviewed Original Research
2023
Patient Preferences for Postmastectomy Breast Reconstruction
Shammas R, Hung A, Mullikin A, Sergesketter A, Lee C, Reed S, Fish L, Greenup R, Hollenbeck S. Patient Preferences for Postmastectomy Breast Reconstruction. JAMA Surgery 2023, 158: 1285-1292. PMID: 37755818, PMCID: PMC10535024, DOI: 10.1001/jamasurg.2023.4432.Peer-Reviewed Original ResearchConceptsRisk of complicationsBreast reconstructionAbdominal morbidityFlap reconstructionBreast cancerGenetic predispositionPatient-physician discussionsImplant-based reconstructionPostmastectomy breast reconstructionCross-sectional studyChance of complicationsPatient-centered careAdditional operationsHigher educational levelMajor complicationsPreoperative counselingPatient preferencesFlap appearanceTreatment preferencesImplant reconstructionMAIN OUTCOMENew diagnosisPatient valuesComplicationsMean increaseRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseComparison of incident breast cancer cases in the largest national US tumor registries.
Plichta J, Thomas S, Record S, Hyslop T, Hwang E, Greenup R. Comparison of incident breast cancer cases in the largest national US tumor registries. Journal Of Clinical Oncology 2023, 41: 6512-6512. DOI: 10.1200/jco.2023.41.16_suppl.6512.Peer-Reviewed Original ResearchIncident breast cancer casesNumber of patientsRace/ethnicityBreast cancer casesTumor RegistryCase ascertainmentBreast cancerCancer casesPatient countsNon-Hispanic American Indian/Alaska NativesNational tumor registryYear of diagnosisMale breast cancerPopulation cancer registryBreast cancer patientsPacific Islander patientsAmerican Indians/Alaska NativesNon-Hispanic blacksNon-Hispanic whitesChi-square testPublic-use databaseFemale patientsHispanic patientsTreatment patternsCancer RegistrySurgery in the Setting of Metastatic Breast Cancer
Plichta J, Taskindoust M, Greenup R. Surgery in the Setting of Metastatic Breast Cancer. Current Breast Cancer Reports 2023, 15: 37-47. DOI: 10.1007/s12609-023-00476-4.Peer-Reviewed Original ResearchMetastatic breast cancerSurvival benefitBreast cancerSurgical resectionPrimary tumorSelect patient groupsPotential survival benefitPrimary breast tumorsLocoregional treatmentMetastatic diseaseMost patientsPatient groupProspective studyRetrospective studySelect subgroupClinical scenariosBreast tumorsResectionTumorsCancerLimited benefitSurgeryPatientsMixed resultsDiseaseModifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives
Fayanju O, Greenup R, Zafar S, Hyslop T, Hwang E, Fish L. Modifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives. Journal Of Surgical Research 2023, 284: 269-279. PMID: 36610386, PMCID: PMC10020986, DOI: 10.1016/j.jss.2022.11.074.Peer-Reviewed Original ResearchConceptsBreast cancer treatmentBreast cancerModifiable barriersCancer treatmentProvider perspectivesSurgical oncology careBreast cancer careAdvanced practice providersSingle health systemModifiable contributorOncologic careModifiable factorsOncology careCancer careTreatment receiptPatients' perceptionsStage 0Practice providersCare receiptPatientsExemplar quotesThematic analysisSuboptimal communicationHealth systemTreatment costs
2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalenceTreatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapyTreatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2021
ASO Visual Abstract: Contralateral Axillary Nodal Metastases—Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?
Nash A, Thomas S, Plichta J, Fayanju O, Hwang E, Greenup R, Rosenberger L. ASO Visual Abstract: Contralateral Axillary Nodal Metastases—Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer? Annals Of Surgical Oncology 2021, 28: 608-609. DOI: 10.1245/s10434-021-10605-x.Peer-Reviewed Original Research
2020
Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program (NC BCCCP): A review of 90,000 women.
Tait S, Ren Y, Horton C, Oshima S, Thomas S, Wright S, Caesar A, Plichta J, Hwang E, Greenup R, Rosenberger L, DiLalla G, Menendez C, Tolnitch L, Hyslop T, Nelson D, Fayanju O. Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program (NC BCCCP): A review of 90,000 women. Journal Of Clinical Oncology 2020, 38: 101-101. DOI: 10.1200/jco.2020.38.29_suppl.101.Peer-Reviewed Original ResearchBreast cancerHispanic womenRace/ethnicityUnivariate analysisBreast pathologyCervical cancer control programsOverall breast cancer mortalityNH Black raceBreast cancer preventionFirst breast cancerBreast cancer mortalityCancer control programsNational quality benchmarksUnderserved womenBlack raceCancer mortalityTimeline of careAmerican IndiansCancer preventionLonger TTDNH blacksNH whitesMedian TTDEthnic disparitiesNegative binomial regressionThe effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions.
Caddell K, Ren Y, Sampathkumar A, Almond C, Ladipo O, Champ C, Rosenberger L, Greenup R, Plichta J, DiLalla G, Menendez C, Tolnitch L, Hwang E, Hyslop T, Fayanju O. The effect of body mass index (BMI) on survival in patients with breast cancer and obesity-associated conditions. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.29_suppl.203.Peer-Reviewed Original ResearchBody mass indexObesity-associated conditionsUnadjusted overall survivalClass 1 obesityOverall survivalBreast cancer outcomesBreast cancerWorse OSObese patientsOverweight womenMass indexBMI classesCancer outcomesAssociation of BMIEffect of BMINon-Hispanic black womenKaplan-Meier methodNormal-weight womenDiagnosis of obesityProportional hazards modelBreast cancer diagnosisStage 0Hazards modelHypertensionObesityPathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K, Smith B, Alexander B, Moy B, Isakoff S, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research 2020, 26: 2838-2848. PMID: 32046998, PMCID: PMC7299787, DOI: 10.1158/1078-0432.ccr-19-3492.Peer-Reviewed Original ResearchConceptsPathologic complete responseEvent-free survivalBetter event-free survivalNeoadjuvant chemotherapyAdjuvant chemotherapyOverall survivalComplete responseBreast cancerImproved event-free survivalIndividual patient-level dataAdditional adjuvant therapySubsequent adjuvant chemotherapyBreast cancer recurrencePatient-level dataComprehensive Meta-AnalysisAdjuvant settingNeoadjuvant responseAdjuvant therapyMicrometastatic diseaseImproved survivalPrognostic significanceSystemic clearanceCancer recurrenceInclusion criteriaChemotherapyMissing data in breast cancer: Relationship with survival in national databases.
Plichta J, Rushing C, Lewis H, Blazer D, Hyslop T, Greenup R. Missing data in breast cancer: Relationship with survival in national databases. Journal Of Clinical Oncology 2020, 38: e19114-e19114. DOI: 10.1200/jco.2020.38.15_suppl.e19114.Peer-Reviewed Original ResearchOverall survivalNational Cancer RegistryTumor variablesCancer RegistryBreast cancerLarge national cancer registryCox proportional hazards modelInvasive breast cancerPatterns of careInclusion/exclusion criteriaTreatment variablesProportional hazards modelRate of deathWorse OSOncology outcomesN stageOS differenceExclusion criteriaOutcome studiesHazards modelPatientsNCDBSurgery dataGreater riskNational database
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden